The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer☆
Introduction
High-grade serous ovarian carcinomas comprise the majority of the estimated 22,000 new cases of ovarian cancer per year in the United States [1]. Low-grade serous carcinoma constitutes a smaller (5–10%), yet significant proportion of serous carcinoma cases [2], [3]. It is accepted that high-grade and low-grade serous carcinoma arise from molecularly discrete pathways and exhibit divergent clinical behavior [4], [5], [6], [7]. For example, while the overall five-year survival for patients with low-grade SOC is longer compared to high-grade serous carcinoma [8], low-grade serous carcinomas are relatively chemoresistant [9], [10]. Emerging targeted therapies have shown promise in low-grade serous carcinoma [11]; however, the role of secondary surgery remains unclear.
In the setting of recurrent high-grade serous carcinoma, most patients are offered chemotherapy or hormonal therapy, and a small subset of patients may benefit from secondary cytoreductive surgery (SCRS). Retrospective reviews suggest that secondary cytoreduction confers a survival advantage in a highly-selected group of patients with recurrent epithelial histology, particularly patients with platinum-sensitive disease with a single site of recurrence [12], [13]. Ongoing prospective clinical trials such as GOG 213 are attempting to more clearly define the role of secondary cytoreduction [14]. While some studies have included low-grade serous histology [15], none have specifically focused on secondary cytoreduction in this particular patient population. We therefore sought to determine the benefit of secondary cytoreduction in low-grade serous carcinoma, whether cytoreduction to no gross residual disease had an impact on progression-free and overall survival (PFS, OS), and whether certain patient characteristics could identify ideal candidates for SCRS.
Section snippets
Methods
After obtaining approval from the Institutional Review Board at the University of Texas MD Anderson Cancer Center, women with a diagnosis of low-grade serous carcinoma who underwent secondary cytoreduction for disease progression/recurrence between 1995 and 2011 were identified. Patients who met the following inclusion criteria were selected: 1) pathologically confirmed low-grade serous histology at the time of initial and secondary cytoreduction, 2) SCRS performed at MD Anderson Cancer Center,
Results
A total of 41 patients who met inclusion criteria comprised our study cohort. Table 1 displays patient characteristics. Median age at time of initial diagnosis was 41.3 years (range 21–74). Six patients (14.6%) were initially diagnosed with serous LMP tumors prior to their diagnosis of low-grade serous carcinoma; the remaining 35 (85.4%) had low-grade serous carcinoma at the time of initial diagnosis. Most patients were White (76%), and most patients (85.4%) had FIGO stage III or IV disease.
At
Discussion
This study demonstrates that patients with low-grade serous carcinoma who underwent secondary cytoreductive surgery to no gross residual disease experienced a 50-month gain in PFS and a 47.8-month gain in OS from the time of SCRS compared to patients with gross residual disease.
Our findings mirror that of other studies examining SCRS in epithelial ovarian cancer, most of which are comprised of high-grade serous histology. Al Rawahi et al. performed a meta-analysis on 1194 women who underwent
Conflict of interest statement
The authors of this manuscript declare no conflicts of interest.
References (23)
- et al.
Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
Gynecol Oncol
(2007) - et al.
Diverse tumorigenic pathways in ovarian serous carcinoma
Am J Pathol
(2002) - et al.
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gynecol Oncol
(2009) - et al.
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Gynecol Oncol
(2008) - et al.
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
Lancet Oncol
(2013) - et al.
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis
Gynecol Oncol
(2009) - et al.
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential
Obstet Gynecol
(2002) - et al.
Cancer statistics, 2013
CA Cancer J Clin
(2013) Epidemiology of low-grade serous ovarian cancer
Am J Obstet Gynecol
(2008)- et al.
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin
Int J Gynecol Pathol
(2004)
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
Obstet Gynecol
Cited by (44)
Low-grade serous ovarian cancer
2023, Diagnosis and Treatment of Rare Gynecologic CancersSecondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis
2022, Gynecologic OncologyCitation Excerpt :Following the removal of 2366 duplicates, the titles and abstracts of 5296 studies were screened. Of these, 350 studies progressed to the full-text review for eligibility assessment, with eight published studies and one conference abstract ultimately selected for inclusion in the systematic review [17,20–27]. Two of the eight studies were selected for meta-analysis of PFS [20,21] and two for OS [17,21].
Low-grade serous ovarian cancer: State of the science
2020, Gynecologic Oncology
- ☆
This work was supported in part by NCI-DHHS-NIH T32 Training Grant (T32 CA101642) (EKC) and by The Sara Brown Musselman Fund for Serous Ovarian Cancer Research.